Journal article
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Abstract
AIMS: Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion.
METHODS AND RESULTS: Patients with AF and more than one risk factor for stroke were randomized to one of three blinded doses of betrixaban (40, 60, or 80 mg once daily) or unblinded warfarin, adjusted to an international …
Authors
Connolly SJ; Eikelboom J; Dorian P; Hohnloser SH; Gretler DD; Sinha U; Ezekowitz MD
Journal
European Heart Journal, Vol. 34, No. 20, pp. 1498–1505
Publisher
Oxford University Press (OUP)
Publication Date
May 2, 2013
DOI
10.1093/eurheartj/eht039
ISSN
0195-668X